SEARCH

SEARCH BY CITATION

References

  • 1
    Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69e171.
  • 2
    Lloyd-Jones D, Adams R, Carnethon M et al. Heart Disease and Stroke Statistics – 2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 480486.
  • 3
    Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281: 12911297.
  • 4
    Dagenais GR, St-Pierre A, Gilbert P et al. Comparison of prognosis for men with type 2 diabetes mellitus and men with cardiovascular disease. CMAJ 2009; 180: 4047.
  • 5
    Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368: 2936.
  • 6
    Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 14151428.
  • 7
    Field AE, Coakley EH, Must A et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161: 15811586.
  • 8
    Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 12101214.
  • 9
    Astrup A, Finer N. Redefining type 2 diabetes: ‘diabesity’ or ‘obesity dependent diabetes mellitus'? Obes Rev 2000; 1: 5759.
  • 10
    Prevalence of overweight and obesity among adults with diagnosed diabetes – United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep 2004; 53: 10661068.
  • 11
    Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997; 146: 214222.
  • 12
    Bergstrom RW, Newell-Morris LL, Leonetti DL, Shuman WP, Wahl PW, Fujimoto WY. Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men. Diabetes 1990; 39: 104111.
  • 13
    Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999; 84: 137144.
  • 14
    Guerrero-Romero F, Rodriguez-Moran M, Perez-Fuentes R et al. Prediabetes and its relationship with obesity in Mexican adults: The Mexican Diabetes Prevention (MexDiab) Study. Metab Syndr Relat Disord 2008; 6: 1523.
  • 15
    Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 10591062.
  • 16
    Staessen J, Bulpitt C, Fagard R, Joossens JV, Lijnen P, Amery A. Four urinary cations and blood pressure. A population study in two Belgian towns. Am J Epidemiol 1983; 117: 676687.
  • 17
    Staessen J, Fagard R, Lijnen P, Amery A. Body weight, sodium intake and blood pressure. J Hypertens 1989; 7: S19S23.
  • 18
    Wexler R, Feldman D. Initiation of therapy for patients with essential hypertension or comorbid conditions. Prim Care 2006; 33: 887901.
  • 19
    Hossain P, Kawar B, El NM. Obesity and diabetes in the developing world – a growing challenge. N Engl J Med 2007; 356: 213215.
  • 20
    National Institutes of Health. National diabetes statistics, 2007. Available from URL: http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm. Accessed 25 September 2009.
  • 21
    Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905912.
  • 22
    Zhang R, Reisin E. Obesity-hypertension: the effects on cardiovascular and renal systems. Am J Hypertens 2000; 13: 13081314.
  • 23
    Schneider R, Golzman B, Turkot S, Kogan J, Oren S. Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005; 330: 157160.
  • 24
    Stewart KJ, Ouyang P, Bacher AC, Lima S, Shapiro EP. Exercise effects on cardiac size and left ventricular diastolic function: relationships to changes in fitness, fatness, blood pressure and insulin resistance. Heart 2006; 92: 893898.
  • 25
    Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374381.
  • 26
    Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 10531059.
  • 27
    Libby P. Fat fuels the flame: triglyceride-rich lipoproteins and arterial inflammation. Circ Res 2007; 100: 299301.
  • 28
    American Heart Association. Cardiovascular disease statistics. Available from URL: http://www.americanheart.org/presenter.jhtml?identifier=4478. Accessed 25 September 2009.
  • 29
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229234.
  • 30
    Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324: 939942.
  • 31
    MacLeod MJ, McLay J. Drug treatment of hypertension complicating diabetes mellitus. Drugs 1998; 56: 189202.
  • 32
    Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 21402144.
  • 33
    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383393.
  • 34
    Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 2008; 31: 102104.
  • 35
    Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 15351540.
  • 36
    American Diabetes Association. Standards of medical care in diabetes – 2008. Diabetes Care 2008; 31(Suppl. 1): S12S54.
  • 37
    Villareal DT, Banks MR, Patterson BW, Polonsky KS, Klein S. Weight loss therapy improves pancreatic endocrine function in obese older adults. Obesity (Silver Spring) 2008; 16: 13491354.
  • 38
    Genuth SM. Insulin secretion in obesity and diabetes: an illustrative case. Ann Intern Med 1977; 87: 714716.
  • 39
    Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393403.
  • 40
    Pi-Sunyer X, Blackburn G, Brancati FL et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 13741383.
  • 41
    Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003; 32: 805822, viii.
  • 42
    Sacks FM, Svetkey LP, Vollmer WM et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 310.
  • 43
    Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 14991504.
  • 44
    Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim Care 2003; 30: 465491.
  • 45
    Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005: 165.
  • 46
    Dansinger ML, Tatsioni A, Wong JB, Chung M, Balk EM. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med 2007; 147: 4150.
  • 47
    Franz MJ, VanWormer JJ, Crain AL et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007; 107: 17551767.
  • 48
    Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003; CD004094.
  • 49
    Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 11941199.
  • 50
    Tice JA, Karliner L, Walsh J, Petersen AJ, Feldman MD. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med 2008; 121: 885893.
  • 51
    Dixon JB, O’Brien PE, Playfair J et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299: 316323.
  • 52
    Pinheiro JS, Schiavon CA, Pereira PB, Correa JL, Noujaim P, Cohen R. Long-long limb Roux-en-Y gastric bypass is more efficacious in treatment of type 2 diabetes and lipid disorders in super-obese patients. Surg Obes Relat Dis 2008; 4: 521525.
  • 53
    Pontiroli AE, Pizzocri P, Librenti MC et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab 2002; 87: 35553561.
  • 54
    Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248256.
  • 55
    Mittermair RP, Aigner F, Obermuller S. Results and complications after Swedish adjustable gastric banding in older patients. Obes Surg 2008; 18: 15581562.
  • 56
    Marinella MA. Anemia following Roux-en-Y surgery for morbid obesity: a review. South Med J 2008; 101: 10241031.
  • 57
    Lieske JC, Kumar R, Collazo-Clavell ML. Nephrolithiasis after bariatric surgery for obesity. Semin Nephrol 2008; 28: 163173.
  • 58
    Sasse KC, Ganser J, Kozar M et al. Seven cases of gastric perforation in Roux-en-Y gastric bypass patients: what lessons can we learn? Obes Surg 2008; 18: 530534.
  • 59
    West KM. Diet therapy of diabetes: an analysis of failure. Ann Intern Med 1973; 79: 425434.
  • 60
    UKPDS Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism 1990; 39: 905912.
  • 61
    Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193203.
  • 62
    Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007; 9: 418427.
  • 63
    National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 2000; 160: 898904.
  • 64
    Foreyt JP, Poston WS. The challenge of diet, exercise and lifestyle modification in the management of the obese diabetic patient. Int J Obes Relat Metab Disord 1999; 23(Suppl. 7): S5S11.
  • 65
    Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386399.
  • 66
    Yu AP, Wu EQ, Birnbaum HG et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007; 23: 21572169.
  • 67
    Grant R, Adams AS, Trinacty CM et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 2007; 30: 807812.
  • 68
    Ziemer DC, Miller CD, Rhee MK et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ 2005; 31: 564571.
  • 69
    Triplitt C, McGill JB, Porte D Jr, Conner CS. The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. J Manag Care Pharm 2007; 13: S2S16.
  • 70
    UK Prospective Diabetes Study (UKPDS) Group. UKPDS Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837853.
  • 71
    Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 25602572.
  • 72
    Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 25452559.
  • 73
    Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008; 358: 26302633.
  • 74
    Krumholz HM, Lee TH. Redefining quality – implications of recent clinical trials. N Engl J Med 2008; 358: 25372539.
  • 75
    Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 17651772.
  • 76
    Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360372.
  • 77
    Albertini JP, McMorn SO, Chen H, Mather RA, Valensi P. Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. Atherosclerosis 2007; 195: e159e166.
  • 78
    Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737754.
  • 79
    Van De Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van WC. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; CD003639.
  • 80
    Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting GLP-1 analogue attenuates induction of PAI-1 and vascular adhesion molecules. J Endocrinol 2009; 201: 5966.
  • 81
    Rosenstock J, Hassman DR, Madder RD- et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004; 27: 12651270.
  • 82
    Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. The Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23: 16051611.
  • 83
    Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 26322637.
  • 84
    Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436447.
  • 85
    Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890895.
  • 86
    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 26382643.
  • 87
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486494.
  • 88
    Courreges JP, Vilsboll T, Zdravkovic M et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008; 25: 11291132.
  • 89
    DeFronzo RA, Goodman AM. The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541549.
  • 90
    Fonseca VA, Theuma P, Mudaliar S, Leissinger CA, Clejan S, Henry RR. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. J Diabetes Complications 2006; 20: 1420.
  • 91
    Gonzalez-Clemente JM. Improvement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes. Eur J Clin Invest 2008; 38: 174179.
  • 92
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 5664.
  • 93
    Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 12691274.
  • 94
    Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 1999; 22: 3337.
  • 95
    Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 1994; 17: 2029.
  • 96
    Lund SS, Tarnow L, Stehouwer CD et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008; 158: 631641.
  • 97
    Manzella D, Grella R, Abbatecola AM, Paolisso G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 2005; 28: 366371.
  • 98
    Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999; 43: 155166.
  • 99
    Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 13441350.
  • 100
    Mistry GC, Maes AL, Lasseter KC et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48: 592598.
  • 101
    Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 14481460.
  • 102
    Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132138.
  • 103
    Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich) 2006; 8: 1928.
  • 104
    Raslova K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007; 27: 279285.
  • 105
    Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 175185.
  • 106
    Rosenstock J, Foley JE, Rendell M et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 3035.
  • 107
    Russell-Jones DS, Shaw J, Brandle M et al. The once-daily human glucagon-like peptide-1 analog liraglutide reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline. Diabetes 2008; 57: A593A594.
  • 108
    Vilsboll T, Zdravkovic M, Le Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 16081610.
  • 109
    Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473481.
  • 110
    Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 20462055.
  • 111
    Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 26282635.
  • 112
    DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 10921100.
  • 113
    U.K. Prospective Diabetes Study Group (UKPDS). U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 12491258.
  • 114
    Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501506.
  • 115
    Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004; 21: 568576.
  • 116
    Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008; 10: 10471056.
  • 117
    Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 8490.
  • 118
    Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268278.
  • 119
    Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 12241230.
  • 120
    Nagi DK, Ali VM, Yudkin JS. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabet Med 1996; 13: 753757.
  • 121
    Holman RR. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 2006; 55: S2S5.
  • 122
    Li J, Tian H, Li Q et al. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients – a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 2007; 9: 558565.
  • 123
    Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance. Am J Physiol Endocrinol Metab 2004; 287: E906E911.
  • 124
    Hanefeld M, Fischer S, Schulze J et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732737.
  • 125
    Weng J, Li Y, Xu W et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 17531760.
  • 126
    Zinman B, Hoogwerf BJ, Duran GS et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477485.
  • 127
    Bonora E. Antidiabetic medications in overweight/ obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Int J Clin Pract Suppl 2007; 154: 1928.
  • 128
    Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2008.
  • 129
    Fisman EZ, Motro M, Tenenbaum A. Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects. Adv Cardiol 2008; 45: 154170.
  • 130
    Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867872.
  • 131
    Hundal RS, Krssak M, Dufour S et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 20632069.
  • 132
    Fontbonne A, Charles MA, Juhan-Vague I et al. BIGPRO Study Group. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996; 19: 920926.
  • 133
    Jadhav S, Ferrell W, Greer IA, Petrie JR, Cobbe SM, Sattar N. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2006; 48: 956963.
  • 134
    Choy CK, Rodgers JE, Nappi JM, Haines ST. Type 2 diabetes mellitus and heart failure. Pharmacotherapy 2008; 28: 170192.
  • 135
    Casscells SW, Granger E, Swedorske J et al. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003–2006. Am J Ther 2008; 15: 198205.
  • 136
    Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338: 265266.
  • 137
    Eurich DT, McAlister FA, Blackburn DF et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335: 497.
  • 138
    Evans JM, Donnan PT, Morris AD. Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes. Diabet Med 2002; 19: 685688.
  • 139
    Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517527.
  • 140
    Adams JF, Clark JS, Ireland JT, Kesson CM, Watson WS. Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy. Diabetologia 1983; 24: 1618.
  • 141
    Davies MJ. Insulin secretagogues. Curr Med Res Opin 2002; 18 (Suppl. 1): s22s30.
  • 142
    Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies. Diabetes Care 2008; 31: 16721678.
  • 143
    Pistrosch F, Schaper F, Passauer J, Koehler C, Bornstein SR, Hanefeld M. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. Horm Metab Res 2009; 41: 104108
  • 144
    Acarbose Cardiovascular Evaluation (ACE) study. University of Oxford Diabetes Trials Unit (DTU). Available from URL: http://www.dtu.ox.ac.uk/index.php?maindoc=/ace/overview/php. Accessed 14 September 2009.
  • 145
    Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007; 292: E871E883.
  • 146
    Stolar MW, Hoogwerf BJ, Gorshow SM, Boyle PJ, Wales DO. Managing type 2 diabetes: going beyond glycemic control. J Manag Care Pharm 2008; 14: s2s19.
  • 147
    Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004; 6: 850863.
  • 148
    Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007; 9: 96102.
  • 149
    Schwartz AV. Diabetes, TZDs, and bone: a review of the clinical evidence. PPAR Res 2006; 2006: 24502.
  • 150
    Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008; 19: 129137.
  • 151
    Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 33493354.
  • 152
    Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW. The Troglitazone Study Group. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care 1998; 21: 14621469.
  • 153
    James AP, Watts GF, Mamo JC. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. Diabetes Obes Metab 2005; 7: 381389.
  • 154
    Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 15471554.
  • 155
    Chappuis B, Braun M, Stettler C et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007; 23: 392399.
  • 156
    Duez H, Lamarche B, Uffelman KD et al. Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production. J Clin Endocrinol Metab 2008; 93: 17221729.
  • 157
    Khan MA, St PJ, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25: 708711.
  • 158
    Boyle PJ, King AB, Olansky L et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378396.
  • 159
    Chiarelli F, Di MD. Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag 2008; 4: 297304.
  • 160
    Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49: 633639.
  • 161
    Blaschke F, Caglayan E, Hsueh WA. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. Endocrinol Metab Clin North Am 2006; 35: 561574, ix.
  • 162
    Wang N, Verna L, Chen NG et al. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem 2002; 277: 3417634181.
  • 163
    Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 25312534.
  • 164
    Kotchen TA, Zhang HY, Reddy S, Hoffmann RG. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 1996; 270: R660R666.
  • 165
    Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001; 24: 392397.
  • 166
    Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 12791289.
  • 167
    Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 11801188.
  • 168
    Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008; 10: 12211238.
  • 169
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 24572471.
  • 170
    Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 21252135.
  • 171
    Mannucci E, Monami M, Di Bari M et al. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2009. DOI: 10.1016/j.ijcard.2009.01.064
  • 172
    Brunton SA, Davis SN, Renda SM. Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone 2006; 8(Suppl. 2): S19S26.
  • 173
    Hermansen K, Mortensen LS, Hermansen ML. Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. Vasc Health Risk Manag 2008; 4: 561574.
  • 174
    Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 30803086.
  • 175
    Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993; 42: 17001707.
  • 176
    Davies M. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord 2004; 28(Suppl. 2): S14S22.
  • 177
    DAWN. The DAWN (Diabetes Attitudes, Wishes and Needs) study. Pract Diab Int 2002; 19: 22a24a.
  • 178
    Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26(Suppl. 3): S18S24.
  • 179
    Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009; 180: 385397.
  • 180
    Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008; 81: 184189.
  • 181
    Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; CD005613.
  • 182
    Randeree HA, Omar MA, Motala AA, Seedat MA. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care 1992; 15: 12581263.
  • 183
    Zappe DH, Sowers JR, Hsueh WA et al. Metabolic and antihypertensive effects of combined angiotension receptor blockers and diuretic therapy in prediabetic hypertensive patients with cardiometabolic syndrome. J Clin Hypertens 2008; 10: 894903.
  • 184
    Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007; 46: 13311336.
  • 185
    Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 10931100.
  • 186
    Adler AI, Neil HA, Manley SE, Holman RR, Turner RC. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am Heart J 1999; 138: S353S359.
  • 187
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 15951607.
  • 188
    Sarwar N, Sattar N, Gudnason V, Danesh J. Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. Eur Heart J 2007; 28: 24912497.
  • 189
    Kanoun F, Ben AZ, Zouari B, Ben KF. Insulin therapy may increase blood pressure levels in type 2 diabetes mellitus. Diabetes Metab 2001; 27: 695700.
  • 190
    Davies MJ, Derezinski T, Pedersen CB, Clauson P. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther 2008; 10: 273277.
  • 191
    Triplitt C, Glass L, Miyazaki Y et al. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care 2006; 29: 23712377.
  • 192
    Heise T, Magnusson K, Heinemann L, Sawicki PT. Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension 1998; 32: 243248.
  • 193
    Turner RC, Cull CA, Frighi V, Holman RR. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 20052012.
  • 194
    Erle G, Lovise S, Stocchiero C et al. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. Acta Diabetol 1999; 36: 6165.
  • 195
    Israili ZH, Hernandez-Hernandez R, Valasco M. The future of antihypertensive treatment. Am J Ther 2007; 14: 121134.
  • 196
    Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412419.
  • 197
    Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
  • 198
    Wofford MR, Smith G, Minor DS. The treatment of hypertension in obese patients. Curr Hypertens Rep 2008; 10: 143150.
  • 199
    Siegel D, Meier J, Maas C, Lopez J, Swislocki AL. The effect of body mass index on fasting blood glucose after initiation of thiazide therapy in hypertensive patients. Am J Hypertens 2008; 21: 438442.
  • 200
    Otero ML, Claros NM. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. Clin Ther 2005; 27: 166173.
  • 201
    Klauser R, Prager R, Gaube S et al. Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus. Hypertension 1991; 17: 1521.
  • 202
    Fonseca V, Bakris GL, Bell DS et al. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med 2007; 24: 759763.
  • 203
    Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin 2004; 20: 16251631.
  • 204
    Ryden L, Standl E, Bartnik M et al. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007; 28: 88136.
  • 205
    Gojanovic B, Feihl F, Liaudet L, Waeber B. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J Renin Angiotensin Aldosterone Syst 2008; 9: 19.
  • 206
    Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68: 12071225.
  • 207
    Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611616.
  • 208
    Yusuf S, Gerstein H, Hoogwerf B et al. Ramipril and the development of diabetes. JAMA 2001; 286: 18821885.
  • 209
    Bosch J, Yusuf S, Gerstein HC et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 15511562.
  • 210
    Siegel D, Swislocki AL. Effects of antihypertensives on glucose metabolism. Metab Syndr Relat Disord 2007; 5: 211219.
  • 211
    Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463473.
  • 212
    McGuire DK, Winterfield JR, Rytlewski JA, Ferrannini E. Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. Diab Vasc Dis Res 2008; 5: 5966.
  • 213
    National Heart LaBI. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Available from URL: http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.htm. Accessed 25 September 2009.
  • 214
    ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 29812997.
  • 215
    Savage PJ, Pressel SL, Curb JD et al. SHEP Cooperative Research Group. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. Arch Intern Med 1998; 158: 741751.
  • 216
    Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 2935.
  • 217
    Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006; 29: 10651070.
  • 218
    Meier J, Maas C, Lopez J, Swislocki A, Siegel D. Body mass index and fasting blood glucose after initiation of thiazide therapy. Presented at: American Heart Association Scientific Sessions; November 13–16, 2005; Dallas, TX.
  • 219
    Weidmann P, De Courten M, Ferrari P. Effect of diuretics on the plasma lipid profile. Eur Heart J 1992; (13 Suppl. G): 6167.
  • 220
    Weinberger MH. Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid levels. Eur Heart J 1992; (13 Suppl. G): 59.
  • 221
    Trost BN, Weidmann P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens Suppl 1987; 5: S81S104.
  • 222
    Houston MC. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J 1988; 115: 640656.
  • 223
    Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201207.
  • 224
    Kuti EL, Baker WL, White CM. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker. Curr Med Res Opin 2007; 23: 12391244.
  • 225
    Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1992; 1: 92101.
  • 226
    Pollare T, Lithell H, Morlin C, Prantare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989; 7: 551559.
  • 227
    Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298: 11521157.
  • 228
    UK Prospective Diabetes Study Group (UKPDS). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713720.
  • 229
    Rossner S, Taylor CL, Byington RP, Furberg CD. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990; 300: 902903.
  • 230
    Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 9951003.
  • 231
    Ostergren J, Poulter NR, Sever PS et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patient with type II diabetes. J Hypertens 2008; 26: 21032111.
  • 232
    Saaddine JB, Cadwell B, Gregg EW et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med 2006; 144: 465474.
  • 233
    Eguchi K, Pickering TG, Kario K. Why is blood pressure so hard to control in patients with type 2 diabetes? J Cardiometab Syndr 2007; 2: 114118.
  • 234
    Costa J, Borges M, David C, Vaz CA. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006; 332: 11151124.
  • 235
    AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13(Suppl. 1): 168.
  • 236
    Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005; 28: 595599.
  • 237
    Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31: 14791484.
  • 238
    Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153165.
  • 239
    Pratley R. Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Endocrinol Metab Clin North Am 2006; 35(Suppl. 1): 611.
  • 240
    Lugari R, Dei Cas A, Ugolotti D et al. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res 2002; 34: 150154.
  • 241
    Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609613.
  • 242
    Prigeon RL, Quddusi S, Paty B, D’Alessio DA. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 2003; 285: E701E707.
  • 243
    Degn KB, Juhl CB, Sturis J et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 11871194.
  • 244
    Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 29292940.
  • 245
    Matthews D, Marre M, Le-Thi T, Zdravkovic M, Simo R. Liraglutide, a once-daily human GLP-1 analog, significantly improves β-cell function in subjects with type 2 diabetes. Diabetes 2008; 57: A150A151.
  • 246
    Vilsboll T, Brock B, Perrild H et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic β-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25: 152156.
  • 247
    D’Alessio DA, Prigeon RL, Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 1995; 44: 14331437.
  • 248
    Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824830.
  • 249
    Gutzwiller JP, Drewe J, Goke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541R1544.
  • 250
    Larsen PJ. Mechanisms behind GLP-1 induced weight loss. Exp Clin Endocrinol Diabetes (in press).
  • 251
    Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009; 150: 16801687.
  • 252
    Meier JJ, Gallwitz B, Salmen S et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 27192725.
  • 253
    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 21312157.
  • 254
    Nystrom T, Gutniak MK, Zhang Q et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209E1215.
  • 255
    Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007; 30: 13351343.
  • 256
    Colagiuri S, Frid A, Zdravkovic M, Le-Thi TDL, Vaag A. The once-daily human glucagon-like peptide-1 analog liraglutide reduces systolic blood pressure in patients with type 2 diabetes. Diabetes 2008; 57: A164A165.
  • 257
    Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2007.
  • 258
    Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 7788.
  • 259
    Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 10831091.
  • 260
    Buse JB, Klonoff DC, Nielsen LL et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007; 29: 139153.
  • 261
    Knudsen LB, Nielsen PF, Huusfeldt PO et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 16641669.
  • 262
    Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 3947.
  • 263
    Jendle J, Nauck M, Matthews D et al. Liraglutide, a once-daily human GLP-1 analog, reduces fat percentage, visceral and subcutaneous adipose tissue and hepatic steatosis compared with glimepiride when added to metformin in subjects with type 2 diabetes. Diabetes 2008; 57: A32A33.
  • 264
    Januvia [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2007.
  • 265
    Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 19791987.
  • 266
    Approval in the United States is pending additional trials in patients with renal dysfunction. Available from URL: http://www.novartis.com/newsroom/mediareleases/en/2007/1153741.shtml. Accessed 30 July 2009.
  • 267
    Rosenstock J, Rendell M, Gross J, Fleck P, Wilson C, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without increasing weight gain or hypoglycemia. Diabetes 2008; 57(Suppl. 1): A132.
  • 268
    Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194206.
  • 269
    Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 16961705.
  • 270
    Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 10191027.
  • 271
    Noel R, Braun D, Patterson R, Bloomgren G. Increased risk of acute pancreatitis observed in patients with type 2 diabetes. Pancreas 2008; 37: 487.
  • 272
    FDA. FDA briefing materials: liraglutide. April 2, 2009. Available from URL: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-01-FDA.pdf. Accessed 30 July 2009.
  • 273
    Endocrine and Metabolic Drug Advisory Committee. Novo Nordisk. Liraglutide (injection) NDA22–34. April 2, 2009. Available from URL: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-02-NovoNordisk.pdf. Accessed 30 July 2009.
  • 274
    Hoerger TJ, Ahmann AJ. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes. J Manag Care Pharm 2008; 14: S2S14.